Please login to the form below
PARP inihibitor
This page shows the latest PARP inihibitor news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Talzenna cleared for breast cancer in Europe
Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Meanwhile, Pfizer’s drug will also have to compete with two
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
